4 Stocks Make It On Today's Healthcare & Biotech Stock Watchlist
Powered by HealthTechMovers.com
We added 4 stocks to our Healthcare & Biotech Stock Watchlist today because they are receiving Bullish Sentiment from investors and financial bloggers.
In addition, they are generating positive media buzz and/or have insider trading signals which came to our attention. This list below is subject to change on a daily basis, so please be sure you subscribe to our email newsletter.
Celldex Therapeutics, Inc., CLDX
Summary: CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.
- Last Price: $41.21
- Price Change: $-1.00, -2.37%
- Yearly Gain: 23.53%
- Market Cap: $2.72B
- P/E Ratio: -14.41
Here are 3rd party ratings for CLDX:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Buy, Top 36% (90 out of 251)
What is the sentiment on the street regarding Celldex Therapeutics, Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bearish
- Blogger Consensus:
- Media Buzz: Sell
- Insider Signal: Balanced
- Investor Sentiment: Positive
- Hedge Fund signal: Medium Risk
If you are interested in CLDX or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on CLDX before you decide to make any investment.
Click here for chart >>
Ligand Pharmaceuticals Incorporated, LGND
Summary: Ligand, being a biotechnology company, focuses on developing/acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure. Ligand's Captisol formulation technology has allowed it to enter into several licensing deals and generate royalties. Captisol is a well validated chemically modified cyclodextrin that is designed to improve safety and solubility, stability, and bioavailability or lessen the volatility, irritation, smell or taste of drugs. Ligand has merged with CyDex. By this, it added an antibody-generating platform, OmniAb, to the company's portfolio. Its other technology platforms include antigen discovery platform & protein expression platform. All these technologies have created a strong platform for Ligand to seek new licenses and partnerships. Ligand has partnership agreements with leading healthcare companies like Novartis, Amgen, Merck, Pfizer, Celgene, Gilead & Lilly, etc. The company continues to buy smaller companies to increase its technology platforms.
- Last Price: $80.36
- Price Change: $7.14, 9.75%
- Yearly Gain: 3.76%
- Market Cap: $1.44B
- P/E Ratio: 26.52
Here are 3rd party ratings for LGND:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Strong Buy, Top 36% (90 out of 251)
What is the sentiment on the street regarding Ligand Pharmaceuticals Incorporated ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bullish
- Blogger Consensus:
- Media Buzz: Neutral
- Insider Signal: Balanced
- Investor Sentiment: Positive
- Hedge Fund signal: Medium Risk
If you are interested in LGND or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on LGND before you decide to make any investment.
Click here for chart >>
Prime Medicine, Inc., PRME
Summary: Prime Medicine Inc. is a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies. Prime Medicine Inc. is based in CAMBRIDGE, Mass.
- Last Price: $5.36
- Price Change: $-0.21, -3.77%
- Yearly Gain: -62.17%
- Market Cap: $643.35M
- P/E Ratio: -2.46
Here are 3rd party ratings for PRME:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Buy, Top 36% (90 out of 251)
What is the sentiment on the street regarding Prime Medicine, Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bullish
- Blogger Consensus:
- Media Buzz: Neutral
- Insider Signal: Selling
- Investor Sentiment: Negative
- Hedge Fund signal: High Risk
If you are interested in PRME or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on PRME before you decide to make any investment.
Click here for chart >>
Jasper Therapeutics, Inc., JSPR
Summary: Jasper Therapeutics Inc., a biotechnology company focused on hematopoietic cell transplant therapies. Jasper Therapeutics Inc., formerly known as Amplitude Healthcare Acquisition Corporation, is based in REDWOOD CITY, Calif.
- Last Price: $21.19
- Price Change: $-1.58, -6.94%
- Yearly Gain: 47.15%
- Market Cap: $319.66M
- P/E Ratio: -0.34
Here are 3rd party ratings for JSPR:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Buy, Top 36% (90 out of 251)
What is the sentiment on the street regarding Jasper Therapeutics, Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bearish
- Blogger Consensus:
- Media Buzz: Sell
- Insider Signal: Buying
- Investor Sentiment: Positive
- Hedge Fund signal: Medium Risk
If you are interested in JSPR or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on JSPR before you decide to make any investment.
Click here for chart >>
Thanks for reading!